Literature DB >> 1746521

Age- and sex-specific incidence rates of migraine with and without visual aura.

W F Stewart1, M S Linet, D D Celentano, M Van Natta, D Ziegler.   

Abstract

Age- and sex-specific incidence rates for the onset of migraine headache with and without preceding visual aura were estimated from a population-based telephone interview survey conducted between March 1986 and June 1987 of 10,169 randomly selected residents of Washington County, Maryland, between the ages of 12 and 29 years. A total of 392 males and 1,018 females were identified as having a history of migraine. Of these, 27% of male cases and 28% of female cases were defined as having migraine with visual aura. Among both males and females, the incidence rate for migraine with visual aura appears to have peaked as much as 3-5 years earlier than the age peak for migraine without aura. For males, the age-specific incidence for migraine with visual aura appears to have peaked on or before 5 years of age at 6.6/1,000 person-years, or possibly higher. In contrast, the highest incidence for migraine without aura occurred between 10 and 11 years of age at 10.1/1,000 person-years. New cases of migraine were uncommon among males in their late 20s. The initial onset of migraine headache begins at a later age among females than among males. For females, the highest incidence of migraine with aura occurred between 12 and 13 years of age at 14.1/1,000 person-years; the highest incidence for migraine without aura occurred between 14 and 17 years of age at 18.9/1,000 person-years. In contrast to males, new onset of migraine was relatively common among females in their late 20s.

Entities:  

Mesh:

Year:  1991        PMID: 1746521     DOI: 10.1093/oxfordjournals.aje.a116014

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  60 in total

1.  Parent-child agreement in the reporting of headaches in a national sample of adolescents.

Authors:  Erin F Nakamura; Lihong Cui; Tarannum Lateef; Karin B Nelson; Kathleen R Merikangas
Journal:  J Child Neurol       Date:  2011-08-10       Impact factor: 1.987

2.  Epidemiology of headache in children and adolescents: evidence of high prevalence of migraine.

Authors:  R Pothmann; S V Frankenberg; B Muller; G Sartory; W Hellmeier
Journal:  Int J Behav Med       Date:  1994

Review 3.  Migraine during pregnancy: options for therapy.

Authors:  Anthony W Fox; Merle L Diamond; Egilius L H Spierings
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 4.  Preventive drugs in childhood and adolescent migraine.

Authors:  Joanne Kacperski; Andrew D Hershey
Journal:  Curr Pain Headache Rep       Date:  2014-06

Review 5.  From 0° to 18°: how headache changes over time.

Authors:  Vincenzo Guidetti; Noemi Faedda
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

6.  Association of benign recurrent vertigo and migraine in 208 patients.

Authors:  Y-H Cha; H Lee; L S Santell; R W Baloh
Journal:  Cephalalgia       Date:  2009-01-16       Impact factor: 6.292

7.  The Zurich Study: XXIII. Epidemiology of headache syndromes in the Zurich cohort study of young adults.

Authors:  K R Merikangas; A E Whitaker; H Isler; J Angst
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

Review 8.  Topiramate in the prevention of pediatric migraine: literature review.

Authors:  Diana Ferraro; Girolamo Di Trapani
Journal:  J Headache Pain       Date:  2008-04-02       Impact factor: 7.277

9.  Pattern of headache in school going children attending specialized clinic in a tertiary care hospital in bangladesh.

Authors:  Md Azharul Hoque; Kazi Mohibur Rahman; Badrul Haque; Rajib Nayan Chowdhury; Sharif Uddin Khan; Atm Hasibul Hasan; Md Badrul Alam Mondol; Monsur Habib; Quazi Deen Mohammad
Journal:  Oman Med J       Date:  2012-09

10.  Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update.

Authors:  Sergio Carmona; Osvaldo Bruera
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.